Eli Lilly and Co. (LLY) Monday announced the completion of its acquisition of Versanis Bio. The deal will add Versanis' lead asset, Bimagrumab to Eli Lilly. Bimagrumab is currently in a Phase 2b study alone and in combination with semaglutide in adults living overweight or obese.
As per the agreement, Versanis shareholders could receive up to $1.925 billion in cash, inclusive of the upfront payment and other milestone payments.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.